Companies
Company news
Articles GetSignal writes with AI from a company's own 8-K filing or press release, newest first. Each one links to the filing or release it was written from.Articles GetSignal writes with AI from a company's own 8-K filing or press release, newest first.
5 articles on TEM
-
Tempus AI receives IVDR certification for xR assay
The certification covers Tempus' quality management system for next-generation sequencing devices for cancer genomic profiling to support clinical management.
-
Tempus AI presents data on AI pre-screening panel for lung cancer
The panel achieved greater than 80% sensitivity across all 12 biomarkers assessed, with sensitivity exceeding 90% for several.
-
Tempus expands multi-year collaboration with Moderna and Merck
The collaboration centers on intismeran autogene, being evaluated with KEYTRUDA in patients with completely resected stage IIB-IV melanoma.
-
Tempus AI has 13 abstracts accepted for ESMO Congress 2026
The European Society for Medical Oncology congress takes place October 23 to 27, 2026, in Madrid.
-
Tempus AI receives FDA 510(k) clearance for its ECG-MR AI product
The product analyzes standard 12-lead resting electrocardiograms to detect signs of undiagnosed moderate or severe mitral regurgitation.
How these are written
- The source: the company's own 8-K filing or press release, linked from every article. What the company says is attributed to the company.
- The checks: each article is written by GetSignal with AI and checked against its source before it is shown.
- The date: the day the company filed the 8-K or published the release.
- Not investment advice. An article reports what the company disclosed; it is not a view on the stock.
Follow companies on GetSignal
Their filings, insider trades and company news in one feed. Free on iPhone and Android.
